ESR1 and neoplasm: Inhibiting PI3K affects tumor growth in estrogen receptor (ER)-positive breast cancer and activates glucocorticoid-regulated kinase 1 through KMT2D, regulating ER-dependent transcription via a negative feedback loop (126, 210).